Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder

Biederman, Joseph; Mick, Eric O.; Surman, Craig; Doyle, Robert; Hammerness, Paul; Michel, Evan; Martin, Jessica; Spencer, Thomas J
January 2007
BMC Psychiatry;2007, Vol. 7, p49
Academic Journal
Background: The main aim of this study was to compare the safety and efficacy of IR MPH administered three times daily to those of once daily OROS-MPH. Methods: Subjects were outpatient adults satisfying full diagnostic criteria for DSM-IV ADHD between 19 and 60 years of age. Data from two independently conducted 6-week placebo controlled, randomized clinical trials of IR-MPH (tid) and of OROS-MPH were pooled to create three study groups: Placebo (N = 116), IR-MPH (tid) (N = 102) and OROS-MPH (N = 67). Results: Eight-five percent (N = 99) of placebo treated subjects, 77% (N = 79) of the IR-MPH (tid) treated subjects, and 82% (N = 55) of the OROS-MPH treated subjects completed the 6-week trial. Total daily doses at endpoint were 80.9 ± 31.9 mg, 74.8 ± 26.2 mg, and 95.4 ± 26.3 mg in the OROS-MPH, IR-MPH (tid), and placebo groups, respectively. At endpoint, 66% (N = 44) of subjects receiving OROS-MPH and 70% (N = 71) of subjects receiving IR-MPH (tid) were considered responders compared with 31% (N = 36) on placebo. Conclusion: Comparison of data from two similarly designed, large, randomized, placebocontrolled, trials, showed that equipotent daily doses of once daily OROS-MPH had similar efficacy to that of TID administered IR MPH. Trial Registration: The trial of OROS-MPH was registered at clinicaltrials.gov, number NCT00181571.


Related Articles

  • The efficacy of 2 different dosages of methylphenidate in treating adults with attention-deficit hyperactivity disorder. Bouffard, Rachelle; Hechtman, Lily; Minde, Klaus; Iaboni-Kassab, Fiorella // Canadian Journal of Psychiatry;Sep2003, Vol. 48 Issue 8, p546 

    Objective: To evaluate the efficacy of methylphenidate in treating adults with attention-deficit hyperactivity disorder (ADHD), using subjective (self-report) and objective (computerized test) measures.Method: This double-blind crossover trial of placebo vs...

  • Methylphenidate.  // Reactions Weekly;9/18/2010, Issue 1319, p32 

    The article describes the cases of three patients who presented with psychotic symptoms while receiving treatment with methylphenidate for attention-deficit/hyperactivity disorder (ADHD), referencing a study published in the August 2010 issue of the journal "Clinical Neuropharmacology."

  • Methylphenidate.  // Reactions Weekly;3/22/2008, Issue 1194/1195, p24 

    The article describes the case of a 22-year-old woman with attention deficit hyperactivity disorder who developed pseudolymphoma during treatment with methylphenidate. The patient experienced recurrent, mildly pruritic crops of painless lesions that were mostly localised to her proximal upper...

  • Atomoxetine Effects on Executive Function as Measured by the BRIEF-A in Young Adults with ADHD: A Randomized, Double-Blind, Placebo-Controlled Study. Adler, Lenard A.; Clemow, David B.; Williams, David W.; Durell, Todd M. // PLoS ONE;Aug2014, Vol. 9 Issue 8, p1 

    Objective: To evaluate the effect of atomoxetine treatment on executive functions in young adults with attention-deficit/hyperactivity disorder (ADHD). Methods: In this Phase 4, multi-center, double-blind, placebo-controlled trial, young adults (18–30 years) with ADHD were randomized to...

  • Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Krause, Johanna; La Fougere, Christian; Krause, Klaus-Henning; Ackenheil, Manfred; Dresel, Stefan H. // European Archives of Psychiatry & Clinical Neuroscience;2005, Vol. 255 Issue 6, p428 

    In this study, we investigated whether availability of striatal dopamine transporter (DAT) may have an influence on the response of adult patients with attention deficit hyperactivity disorder (ADHD) on methylphenidate (MPH). In 18 non–smoking and non–medicated adult patients with...

  • Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder. Weisler, Richard H.; Pandina, Gahan J.; Daly, Ella J.; Cooper, Kimberly; Gassmann-Mayer, Cristiana // CNS Drugs;2012, Vol. 26 Issue 5, p421 

    Background: Psychostimulants, including methylphenidate and amphetamine preparations, are commonly prescribed for the treatment of attention-deficit hyperactivity disorder (ADHD) in children and adults. Histamine H3 recep-tors reside on non-histamine neurons and regulate other neurotransmitters...

  • Non-specific effects of methylphenidate (Ritalin) on cognitive ability and decision-making of ADHD and healthy adults. Agay, Nirit; Yechiam, Eldad; Carmel, Ziv; Levkovitz, Yechiel // Psychopharmacology;Jul2010, Vol. 210 Issue 4, p511 

    The effect of a single dose of methylphenidate (MPH) on cognitive measures and decision-making processes was assessed in a sample of adults with ADHD and in a control sample. Thirty-two adults satisfying DSM-IV criteria for ADHD and 26 healthy controls performed several cognitive tasks. Half of...

  • Response to methylphenidate in children and adolescents with ADHD: does comorbid anxiety disorders matters? Garcia, Sheila; Guimarães, Julia; Zampieri, Juliana; Martinez, Ana; Polanczyk, Guilherme; Rohde, Luis // Journal of Neural Transmission;May2009, Vol. 116 Issue 5, p631 

    There are controversial evidence in the literature on the role of comorbid anxiety disorders (ANX) in the improvement of attention-deficit/hyperactivity disorder (ADHD) symptoms with methylphenidate (MPH) treatment. Our main objective was to assess differences in the response to MPH treatment in...

  • Is methylphenidate a useful treatment for cancer-related fatigue in children? Sharp, Victoria; Finlay, Fiona; Kevitiyagala, Diluki // Archives of Disease in Childhood;Jan2013, Vol. 98 Issue 1, p80 

    The article offers information on the effectiveness of methylphenidate in the treatment for cancer-related fatigue in children. The article presents unavailability of any evidence regarding the use of methylphenidate for treating cancer-related fatigue in children as various medical databases...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics